Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II
TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...
Arch Biopartners
Advertisement
Arch Biopartners Expands LSALT Peptide Phase 2 Kidney Injury Trial to U.S.
TORONTO, Canada, August 11, 2026 Arch Biopartners Inc. announced plans to expand its ongoing Phase 2 clinical trial of...
Arch Biopartners Accelerates IL-32 Chronic Kidney Disease Drug Program
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
Arch Biopartners Expands Phase II Kidney Injury Trial in Canada
TORONTO, November 5, 2025 — Arch Biopartners Inc. (TSXV: ARCH, OTCQB: ACHFF) announced that the Fraser Health Research Ethics...
Advertisement
